HORAN Wealth LLC Grows Holdings in Bristol Myers Squibb Company $BMY

HORAN Wealth LLC raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 100.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,456 shares of the biopharmaceutical company’s stock after purchasing an additional 9,229 shares during the quarter. HORAN Wealth LLC’s holdings in Bristol Myers Squibb were worth $1,032,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Swiss RE Ltd. purchased a new position in Bristol Myers Squibb in the 4th quarter worth about $25,000. Physician Wealth Advisors Inc. boosted its position in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 202 shares during the period. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb in the 2nd quarter worth about $25,000. Bayban bought a new position in Bristol Myers Squibb in the 4th quarter worth about $31,000. Finally, EQ Wealth Advisors LLC purchased a new position in shares of Bristol Myers Squibb during the fourth quarter worth approximately $32,000. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Trading Down 0.7%

Shares of NYSE BMY opened at $60.30 on Tuesday. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The stock has a market capitalization of $123.14 billion, a P/E ratio of 16.94, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The business has a fifty day moving average price of $57.11 and a 200 day moving average price of $57.85.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts expect that Bristol Myers Squibb Company will post 6.34 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on BMY shares. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Bank of America lowered their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. Finally, Weiss Ratings lowered Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $61.25.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb expanded its NVIDIA partnership and plans to deploy a DGX SuperPOD based on Vera Rubin systems, which the company says will become the most powerful AI factory in life sciences and should enhance drug discovery and development efficiency. Bristol Myers Expands NVIDIA Partnership to Build Top Life Sciences AI Supercomputer
• Positive Sentiment: The company also said it will be the first life sciences firm to buy Nvidia’s latest DGX SuperPOD system, signaling an aggressive investment in AI infrastructure that could strengthen Bristol Myers’ competitive position in future drug research. Bristol Myers buys Nvidia’s latest AI computing system for drug research
• Neutral Sentiment: A Reuters report repeated the AI-infrastructure news, reinforcing the strategic nature of the announcement but adding no materially new information for investors. Bristol Myers buys Nvidia’s latest AI computing system for drug research
• Neutral Sentiment: Bristol Myers was mentioned in a broader article about cancer-drug competition and next-generation therapies, but the piece mainly discussed the market landscape rather than any company-specific development. Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.
• Negative Sentiment: Healthcare stocks fell late Monday afternoon, which may be creating a modest drag on BMY and offsetting some of the optimism from the NVIDIA partnership news. Sector Update: Healthcare Stocks Fall Late Afternoon

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.